INX-315, a CDK2 inhibitor, gained FDA fast track status in CCNE1-positive platinum-resistant/refractory ovarian cancer.

Northwestern Medicine scientists have identified a key driver of chemotherapy resistance in advanced ovarian cancer, ...

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 6.64%, which has investors questioning if this is right time ...

Terri Baker was diagnosed with stage 4 ovarian cancer in September. Today, the cancer is undetectable. When Terri Baker ...

Malla Reddy Narayana Hospital, Hyderabad is a premier cancer care centre in Telangana, announced a remarkable medical ...

Data shows Norway, which is similar in population size to NZ, increased its five-year survival rates for ovarian cancer from 34.1% to 46.1% in the almost two decades from 1995. In contrast, New ...

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract highlighting new, highly encouraging, Overall Survival ...

As shown in Figure 2, peritoneal tissues ... to intravenous chemotherapy produces significantly longer progression-free and overall survival in ovarian cancer patients with small tumors (<1 ...